The morning after: what now for psychiatry research?
Simon Wessely1,2, Krista Nicholson3
1Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neurosciences, Kings College London, Weston Education Centre, Cutcombe Road, London, UK. simon.wessely@kcl.ac.uk.
Abstract:
The UK scientific community is rightly concerned about the impact of leaving the EU on UK science. These concerns are particularly pertinent for mental health research, which is chronically underfunded in comparison to research on physical health conditions. The EU is one of the largest funders of mental health research in the world, with the UK clearly benefitting from this because of its strong track record. Any loss of funding, leadership or influence would weaken this. Likewise if we are unable to attract the best or most promising researchers from the rest of Europe, the loser will not just be research into mental health across Europe, but patients themselves. Those working on the Brexit negotiations must develop clear and coherent plans to safeguard scientific research in UK and ensure that the momentum gained in mental health policy in recent years is not lost.
Related Concept Videos
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
01:54The Placebo Effect
01:29The Influence of Affect on Cognition
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:53Cause and Effect